This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OASM vs. NRBO, SPRB, AEZS, CPHI, GRAY, OGEN, NBY, CANF, ADXS, and UPCShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include NeuroBo Pharmaceuticals (NRBO), Spruce Biosciences (SPRB), Aeterna Zentaris (AEZS), China Pharma (CPHI), Graybug Vision (GRAY), Oragenics (OGEN), NovaBay Pharmaceuticals (NBY), Can-Fite BioPharma (CANF), Ayala Pharmaceuticals (ADXS), and Universe Pharmaceuticals (UPC). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. Its Competitors NeuroBo Pharmaceuticals Spruce Biosciences Aeterna Zentaris China Pharma Graybug Vision Oragenics NovaBay Pharmaceuticals Can-Fite BioPharma Ayala Pharmaceuticals Universe Pharmaceuticals NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Is NRBO or OASM more profitable? NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroBo PharmaceuticalsN/A -189.12% -122.31% Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92% Do institutionals & insiders believe in NRBO or OASM? 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, NRBO or OASM? NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Which has preferable earnings & valuation, NRBO or OASM? NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Oasmia Pharmaceutical AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/AOasmia Pharmaceutical AB (publ)$220K6.82-$18.95MN/AN/A Does the media refer more to NRBO or OASM? In the previous week, NeuroBo Pharmaceuticals' average media sentiment score of 0.00 equaled Oasmia Pharmaceutical AB (publ)'saverage media sentiment score. Company Overall Sentiment NeuroBo Pharmaceuticals Neutral Oasmia Pharmaceutical AB (publ) Neutral SummaryNeuroBo Pharmaceuticals and Oasmia Pharmaceutical AB (publ) tied by winning 4 of the 8 factors compared between the two stocks. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OASM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$823.78M$5.82B$9.71BDividend YieldN/A4.84%3.84%4.09%P/E RatioN/A1.1330.9025.97Price / Sales6.8225.94469.81120.77Price / CashN/A19.5637.1558.38Price / Book0.036.639.116.37Net Income-$18.95M-$4.90M$3.26B$265.56M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.02flatN/AN/A$1.50M$220K0.0057NRBONeuroBo PharmaceuticalsN/A$0.64-1.6%N/A-83.6%$5.51MN/A0.0010SPRBSpruce Biosciences2.116 of 5 stars$8.92-0.4%$131.25+1,372.2%-76.7%$5.01M$4.91M-9.4820Gap DownAEZSAeterna ZentarisN/A$2.63-9.0%N/A-52.6%$4.72M$2.37M-0.1820High Trading VolumeCPHIChina Pharma0.9168 of 5 stars$1.43+1.1%N/A-92.7%$4.67M$4.40M0.00250GRAYGraybug VisionN/A$2.94+1.1%N/A-29.5%$4.62MN/A-1.7027Positive NewsHigh Trading VolumeOGENOragenics0.4639 of 5 stars$1.08+1.9%N/A-96.2%$4.46MN/A-0.155Short Interest ↓NBYNovaBay Pharmaceuticals0.3829 of 5 stars$1.03+71.7%$0.85-17.5%+97.8%$3.49M$9.78M-0.0230Gap UpHigh Trading VolumeCANFCan-Fite BioPharma1.989 of 5 stars$0.66+3.5%$14.00+2,030.9%-70.7%$2.33M$674K-0.378Negative NewsADXSAyala PharmaceuticalsN/A$0.05flatN/A+158.5%$2.26M$3.24M-0.0120UPCUniverse PharmaceuticalsN/A$3.50+2.2%N/A-99.8%$1.97M$19.29M0.00220Gap Up Related Companies and Tools Related Companies NRBO Competitors SPRB Competitors AEZS Competitors CPHI Competitors GRAY Competitors OGEN Competitors NBY Competitors CANF Competitors ADXS Competitors UPC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OASM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access